small molecule

QLONILIK

CLONIDINE HYDROCHLORIDE

Loss of exclusivityAugust 2045latest FDA-listed patent expiry
CompanyCMP DEVELOPMENT LLC

Drug detail

Brand nameQLONILIK
Active ingredientCLONIDINE HYDROCHLORIDE
Strength0.05MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2026
Marketing statusRX

Listed patents

PatentExpiresType
12551466August 2045product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.